Oxford BioDynamics (LON:OBD) Trading 11.1% Higher – What’s Next?

Shares of Oxford BioDynamics Plc (LON:OBD) traded up 11.1% on Friday . The company traded as high as GBX 0.25 and last traded at GBX 0.25. 1,772,000 shares traded hands during trading, a decline of 91% from the average session volume of 19,880,992 shares. The stock had previously closed at GBX 0.23.

Oxford BioDynamics Price Performance

The stock has a market cap of £8.58 million, a P/E ratio of -0.25 and a beta of 0.42. The company has a debt-to-equity ratio of 457.97, a quick ratio of 2.80 and a current ratio of 0.88. The firm has a 50-day moving average price of GBX 0.27 and a 200-day moving average price of GBX 0.33.

Oxford BioDynamics (LON:OBD) last issued its quarterly earnings results on Wednesday, December 24th. The biotechnology company reported GBX (0.80) earnings per share (EPS) for the quarter. Oxford BioDynamics had a negative net margin of 1,018.54% and a negative return on equity of 316.67%.

Oxford BioDynamics Company Profile

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.